Swiss Biotech Stock News

As European markets navigate the challenges of heightened energy prices and geopolitical tensions, investors are increasingly focused on companies that demonstrate resilience and potential for growth. In such uncertain times, stocks with high insider ownership can signal strong confidence from those who know the business best, making them attractive candidates for consideration in a volatile market environment.

Earnings event puts Banque Cantonale de Genève in focus Banque Cantonale de Genève (SWX:BCGE) has drawn fresh attention after reporting full year 2025 results, with net interest income of CHF 347.8 million and net income of CHF 220.89 million. See our latest analysis for Banque Cantonale de Genève. The earnings release comes after a strong run in the share price, with a 90 day share price return of 34.17% and a year to date share price return of 30.89% at a latest share price of CHF32.2,...

Newron Pharmaceuticals (SWX:NWRN) has opened FY 2025 with first half revenue of €11.9 million and a basic EPS loss of €0.00, setting a cautious tone against a share price of CHF 14.64. Over recent periods, the company has seen revenue move from €3.4 million in H1 2024 to €48.0 million in H2 2024 and then to €11.9 million in H1 2025. Basic EPS has shifted from a loss of €0.51 in H1 2024 to a profit of €1.37 in H2 2024 and back to a marginal loss in the latest half, leaving investors focused on...

SKAN Group (SWX:SKAN) has just posted a softer first half for FY 2025, with revenue of CHF134.6 million and a basic EPS loss of CHF0.40, after generating CHF163.7 million in revenue and EPS of CHF0.61 in the first half of FY 2024. Over the last twelve months, revenue has run at CHF333.3 million with basic EPS of CHF0.72. This latest half-year print lands against a backdrop of shrinking trailing net margins, which keeps the focus squarely on how quickly profitability can stabilise. See our...

MCH Group (SWX:MCHN) has opened FY 2025 with half year revenue of CHF 214.2 million and basic EPS of CHF 0.17, while trailing twelve month figures sit at CHF 401.6 million of revenue and basic EPS of CHF 0.15 as the company builds on its recent move into profitability. Over the past reported periods, revenue has moved from CHF 233.8 million in the first half of 2024 to CHF 187.4 million in the second half of 2024 and then to CHF 214.2 million in the first half of 2025. Over the same periods,...

INFICON Holding FY 2025 Earnings Snapshot INFICON Holding (SWX:IFCN) has posted its FY 2025 results with second half revenue of US$348.0 million and basic EPS of US$1.74, alongside net income of US$42.6 million, setting the tone for how the year closed out. The company has seen revenue move from US$349.8 million and basic EPS of US$2.48 in 2H 2024 to US$348.0 million and US$1.74 in 2H 2025, while trailing twelve month revenue sits at US$673.7 million with EPS of US$3.51, giving a clear read...

Recent share performance and business scale Novartis (SWX:NOVN) shares recently closed at CHF 117.48, with a 1 day return of 1.17% and mixed short term moves, including a 3.53% decline over the past week and a 7.10% decline over the past month. Over longer periods, the stock shows a 6.70% total return over the past 3 months, 8.28% year to date, and 23.68% over the past year, with multi year total returns also in positive territory. The company reports revenue of CHF 56.67b and net income of...

If you are wondering whether Compagnie Financière Tradition is attractively priced today, the recent share performance gives some useful clues about how the market currently views the stock. The share price closed at CHF 265.0, with a 4.0% decline over the last 7 days and a 1.5% decline over 30 days, while longer term returns sit at 34.4% over 1 year and 161.2% over 3 years. Recent coverage has focused on Compagnie Financière Tradition in the context of its share price returns and broader...

As European markets face heightened uncertainty due to geopolitical tensions and rising energy costs, the STOXX Europe 600 Index has seen a decline of 3.79%, reflecting investor caution. In this environment, identifying stocks that are potentially undervalued can be an effective strategy for investors looking to capitalize on discrepancies between current market prices and intrinsic value estimates.

As European markets navigate heightened uncertainty stemming from geopolitical tensions and rising energy costs, investors are increasingly focusing on companies with strong fundamentals and insider confidence. In this environment, growth stocks with substantial insider ownership can offer a unique perspective on potential resilience and alignment of interests between management and shareholders.

Stadler Rail AG's ( VTX:SRAIL ) stock was strong after they recently reported robust earnings. We did some analysis and...

Even though Orell Füssli AG's ( VTX:OFN ) recent earnings release was robust, the market didn't seem to notice...

A lackluster earnings announcement from StarragTornos Group AG ( VTX:STGN ) last week didn't sink the stock price. Our...

Investis Holding SA's ( VTX:IREN ) recent weak earnings report didn't cause a big stock movement. However, we believe...

Logitech International (SWX:LOGN) has drawn fresh attention after announcing a share repurchase plan of up to US$1.4b, alongside the global launch of its Logitech G RS H-Shifter for sim racing enthusiasts. See our latest analysis for Logitech International. The share repurchase news comes after a mixed stretch for the stock. A 2.11% 1-day share price return contrasts with a 7-day decline of 4.33%. Meanwhile, the 3-year total shareholder return of 55.50% stands out against a weaker 1-year...

AI-focused partnership shifts attention toward Tecan Group stock Tecan Group (SWX:TECN) has drawn renewed attention after announcing a collaboration with NVIDIA to integrate GPU-accelerated AI models into its laboratory instruments, with the aim of supporting data driven labs and higher research productivity. See our latest analysis for Tecan Group. The AI partnership headlines arrive after a volatile stretch for the stock, with a 1-day share price return of 9.07% and a 30-day share price...

Dividend increase and bond issue draw fresh attention to ABB (SWX:ABBN) ABB (SWX:ABBN) is on income investors’ radar after its board approved a higher dividend of CHF 0.94 per share at the March 19, 2026 AGM, alongside a new fixed income issuance. See our latest analysis for ABB. Those dividend and bond announcements come after a mixed few weeks for the share price, with a 1 day share price return of 1.02% but a 30 day share price decline of 6.89%, set against a 36.48% 1 year total...

Earnings trigger puts Berner Kantonalbank in focus Berner Kantonalbank (SWX:BEKN) has drawn investor attention after publishing its full year 2025 results, which show lower net interest income and net income and indicate slightly weaker profitability compared with the previous year. See our latest analysis for Berner Kantonalbank. The earnings release comes after a strong rebound in the share price, with a 10.78% 1 month share price return and 29.04% 3 month share price return, contributing...

UBS Group (SWX:UBSG) has secured final approval for a US national banking licence, a regulatory step that allows the Swiss group to add everyday banking products alongside its existing US wealth management offerings. See our latest analysis for UBS Group. Despite the new US banking licence and a proposed cancellation of 63,776,550 repurchased shares, momentum has cooled, with a 30 day share price return of 10.34% decline and a year to date share price return of 22.95% decline, even as the 5...

Cosmo Pharmaceuticals at NVIDIA GTC: Why This AI Conference Matters for Investors Cosmo Pharmaceuticals (SWX:COPN) is set to present at the NVIDIA GTC AI Conference on March 19 in San Jose, putting its MedTech AI capabilities and GI Genius platform in front of a focused AI audience. See our latest analysis for Cosmo Pharmaceuticals. Cosmo’s share price has had a weak short term run, with a 30 day share price return of 33.31% decline and a year to date decline of 24.57%. However, the 1 year...

Earnings event puts INFICON’s 2025 profitability in focus INFICON Holding (SWX:IFCN) has released full year 2025 results, reporting sales of US$673.72 million compared with US$670.95 million a year earlier. Net income was US$85.82 million, down from US$112.75 million. This shift has put profit trends under closer scrutiny for shareholders. See our latest analysis for INFICON Holding. The earnings release, which showed relatively steady sales but a lower net income, comes as INFICON’s 1 year...

Earnings event puts Medartis Holding (SWX:MED) in focus Medartis Holding (SWX:MED) is back on investors’ radar after reporting full year 2025 results, with higher sales, net income and earnings per share, followed by a special call on the same day. See our latest analysis for Medartis Holding. At a share price of CHF83.0, the stock has a 1 day share price return of 4.93% but a 30 day share price return that reflects a 12.17% decline. The 1 year total shareholder return of 9.35% suggests...

In recent weeks, SaltX Technology announced a Joint Development Agreement with Holcim to co-develop and pilot a fully electrified, fossil-free clinker production process in Europe, targeting the world’s first fully electric cement plant by 2028 and advancing electrified calcination and sintering technologies that can be retrofitted or built into new facilities. By pairing this deep-process electrification push with Holcim’s broader moves in low‑carbon manufacturing and equipment procurement,...

Galderma Group stock: recent performance snapshot Galderma Group (SWX:GALD) has drawn fresh attention after a period of mixed share performance, including a 0.3% move over the past day and a negative return over the past month and past 3 months. See our latest analysis for Galderma Group. That recent 7 day and 90 day share price weakness, with a 7 day share price return of a 1.93% decline and a 90 day share price return of a 13.16% decline from CHF142.5, contrasts with a 1 year total...